Among the body's most important organs is the heart. When we think about heart health, we often picture common conditions like heart attacks, high blood pressure or high cholesterol.¹ However, the heart can be affected by something much rarer - tumours.²

Cardiac myxomas are the most common type of benign tumour that grows inside the heart and are particularly associated with a genetic condition known as Carney Complex.³ While these tumours are typically non-cancerous, they can pose serious risks, even leading to sudden death if left undiagnosed. These tumours are particularly dangerous as they grow without any noticeable symptoms, making them harder to detect.³ But with early detection, there’s hope. Understanding these heart tumours is the first step in managing the risk and ensuring a longer, healthier life.

Carney complex 

Carney Complex is a rare genetic disorder that affects multiple parts of the body, leading to the development of various tumours and skin abnormalities.⁴ It is typically caused by mutations in the PRKAR1A gene, which plays a role in regulating cell growth in various tissues. Over time, these tumours can lead to major health issues even though they are mostly benign. The condition follows an autosomal dominant inheritance pattern, meaning that individuals with Carney Complex have a 50% chance of passing it on to their children.

Carney Complex manifests in a variety of ways, with the following being the most common features:⁴

• Skin Pigmentation: Individuals develop distinctive skin lesions, including spotty skin - small, pigmented spots that resemble freckles. Other skin abnormalities, like blue nevi (dark blue or black birthmarks), are also common
• Endocrine Tumours: Patients with Carney Complex are at risk for endocrine tumours, especially those involving the pituitary and adrenal glands. These tumours can lead to hormone imbalances, causing symptoms like Cushing's syndrome
• Myxomas: One of the hallmark features of Carney Complex is the formation of myxomas, which are benign tumours that can occur in multiple organs, most notably the heart, skin and breast

Cardiac myxomas in carney complex

A cardiac myxoma is a non-cancerous tumour that forms inside the heart, typically composed of connective tissue and appears as soft, gelatinous masses.³ It is the most frequent tumour linked to the Carney Complex, which often develops in the atria (the upper chambers of the heart), especially the left atrium.

Cardiac myxomas can cause a variety of symptoms, which may mimic other heart conditions. Common clinical presentations include:

• Embolic Events:⁵ A major concern with cardiac myxomas is the risk of embolism, where tumour fragments or blood clots break loose and travel to other parts of the body. This can lead to serious complications like peripheral embolism (blockage of blood vessels in the limbs or other organs), which can be life-threatening
• Systemic Symptoms:³ In some cases, myxomas can cause systemic symptoms due to the release of various substances from the tumour. These symptoms can include fever, unexplained weight loss and fatigue, which may mimic other systemic conditions and complicate diagnosis

Early detection of cardiac myxomas in people with Carney Complex is crucial for managing risks and improving outcomes.⁴ Regular heart monitoring and imaging are essential to identify these tumours before they cause life-threatening complications. Timely treatment, including tumour removal, allows patients to lead relatively normal lives. Ongoing monitoring for other tumours and abnormalities is also vital to address new developments promptly and minimise health risks.

Risks 

Carney Complex-related cardiac myxomas come with a number of serious risks and complications. One of the most immediate dangers is the risk of sudden death, which can occur if the tumour obstructs normal blood flow or causes an embolism.⁶ Stroke or other embolic events may result from tumour fragments or blood clots that spread to other areas of the body, including the brain.

Another major concern is the risk of recurrence, particularly if the myxoma is not completely removed during surgery.⁶ Even after successful removal, patients with Carney Complex remain at a higher risk for developing new myxomas in the future.

In addition to these risks, cardiac myxomas can lead to systemic and neurological complications.⁶ By obstructing blood flow, the tumour may impair the heart's ability to pump efficiently, potentially leading to heart failure. Additionally, the tumour's interference with heart function may directly lead to the development of arrhythmias. 

While it is rare, there is a potential for malignant transformation of the tumour, turning it into a cancerous growth.⁶ Even though this is uncommon, it is still a potential that needs to be kept an eye on. Overall, due to the tendency for recurrence and other health complications, patients with Carney Complex need regular screening and early intervention to minimise these risks and manage their health effectively.

Diagnosis

The diagnosis of cardiac myxomas typically involves a combination of family and medical history, imaging techniques and genetic testing, especially if there is suspicion of an underlying condition like Carney Complex.^7,8 A detailed family history is important, particularly if there is a history of multiple tumours or skin abnormalities, as cardiac myxomas can be part of hereditary syndromes like Carney Complex.

Diagnosis of cardiac myxomas requires the use of imaging techniques.^7,8 Echocardiograms (both Transthoracic Echocardiogram [TTE] and Transesophageal Echocardiogram [TEE]) are the primary tools for visualising the heart and identifying myxomas. In some cases, MRI or CT scans may be used to provide more detailed images of the heart and other affected organs, helping doctors assess tumour size, location and any potential complications.

If there is a suspicion of Carney Complex or other hereditary conditions, genetic testing to identify mutations in the PRKAR1A gene may be performed.⁸ This verifies if the cardiac myxomas belong to a more extensive hereditary condition.

Diagnosing cardiac myxomas can be challenging, especially when they occur sporadically or when the patient shows no obvious symptoms. Despite being the most common type of primary heart tumour, their rarity and complexity often require a combination of physical exams, imaging tests and genetic screening.³

Treatment & management

Surgical removal is the primary treatment for cardiac myxomas.⁹ This is typically the most effective approach to eliminate the tumour and prevent complications like obstruction or embolism. Due to the delicate location of the tumour, especially if it is in the atria, the surgery often requires careful planning and expertise to minimise risks during and after the procedure.

After surgery, lifelong monitoring is crucial to detect any recurrence of myxoma.⁹ Regular heart imaging, such as echocardiograms, should be done to monitor for the development of new tumours. Additionally, since cardiac myxomas can be associated with Carney Complex, patients should be regularly screened for other potential tumours, such as those in the endocrine glands or skin, to manage the broader impacts of the condition.

Lastly, genetic counselling is recommended for families affected by Carney Complex.¹⁰ This helps to assess the risk of passing on the genetic mutation and provides guidance on family planning, as the condition follows an autosomal dominant inheritance pattern. Early genetic counselling and awareness are vital for managing both the health of the individual and any potential risk to future generations.

Identification 

Early detection of cardiac myxomas significantly reduces the risk of severe complications, such as stroke, heart failure or embolic events.^3,9 When identified and treated early, the prognosis improves substantially, allowing patients to avoid life-threatening outcomes and enjoy a better quality of life.

For individuals with Carney Complex and cardiac myxomas, long-term management requires ongoing care.⁴ A multidisciplinary approach involving cardiologists, geneticists, endocrinologists and other specialists is essential. Regular monitoring, including imaging tests and screenings for other tumours, ensures that any recurrence or new developments are detected early, improving long-term health outcomes and quality of life.

Summary 

Carney Complex significantly increases the risk of developing multiple cardiac myxomas, which can cause severe health complications if left undiagnosed or untreated. Regular monitoring and early detection are essential for preventing life-threatening issues. Due to the genetic nature of the condition, individuals with Carney Complex require lifelong vigilance to manage the risk of myxomas and other associated tumours.

Recognising the symptoms of Carney Complex, including cardiac myxomas, is crucial for early intervention. Additionally, being aware of family history can play a vital role in identifying individuals at risk. Greater awareness among both the general public and healthcare professionals is needed to ensure early diagnosis and appropriate management of the condition.

Advancements in genetics and imaging technologies hold promise for improving the detection, management and treatment of cardiac myxomas and Carney complex. As research progresses, there is hope that outcomes will continue to improve, offering individuals with Carney Complex a better quality of life and reduced health risks in the future.